EIS Performance — iShares MSCI Israel ETF
Data updated: 2026-07-27
EIS returned +25.68% year to date and +65.13% over one year to May 2026. Annualised returns are +40.21% over 3 years and +16.66% over 5 years. The fund beat its Israel Equity category average: $100 invested three years ago grew to $276, against $250 for the category, and to $165 over one year, against $165. Volatility over the past three years was 20.61% a year. In the 12 months to May 2026 the fund took in a net $458.6M, and assets reached $1.03B.
EIS Growth of $100
What $100 invested in iShares MSCI Israel ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Israel Equity category average over the same months.
| Period | EIS | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $165 | $165 |
| 3 years (Jun 2023 – May 2026) | $276 | $250 |
| 5 years (Jun 2021 – May 2026) | $216 | $199 |
| Since data start (Sep 2019 – May 2026) | $284 | $270 |
EIS Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +25.68% |
| 1 year | +65.13% |
| 3 years (annualised) | +40.21% |
| 5 years (annualised) | +16.66% |
EIS Annual Returns
Calendar-year total returns of iShares MSCI Israel ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +25.68% |
| 2025 | +45.59% |
| 2024 | +33.80% |
| 2023 | +5.33% |
| 2022 | −27.00% |
| 2021 | +23.22% |
| 2020 | +11.49% |
| 2019 (Sep–Dec) | +9.79% |
EIS Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.3% | −0.2% | −2.4% | +11.7% | +6.6% | — | — | — | — | — | — | — |
| 2025 | +4.6% | −1.3% | −5.8% | +5.2% | +8.4% | +11.6% | −2.6% | +3.4% | +5.3% | +2.3% | +1.3% | +7.1% |
| 2024 | +0.9% | +8.5% | +0.2% | −7.0% | +4.4% | −1.0% | +2.3% | +8.0% | +0.3% | +1.3% | +8.2% | +4.5% |
| 2023 | +4.5% | −7.7% | +1.1% | −1.4% | −2.7% | +2.9% | +7.2% | −3.9% | −1.1% | −14.4% | +16.7% | +7.6% |
| 2022 | −4.9% | −0.1% | +0.4% | −6.8% | −6.1% | −8.3% | +8.4% | +3.6% | −13.7% | +6.2% | +1.0% | −8.2% |
| 2021 | +0.8% | +0.3% | −0.4% | +6.4% | +0.3% | +1.6% | +2.0% | +1.7% | −0.9% | +6.0% | −1.1% | +4.8% |
| 2020 | +2.9% | −6.3% | −18.1% | +11.2% | +4.7% | −2.4% | +6.7% | +3.2% | −7.6% | +0.9% | +11.9% | +8.2% |
| 2019 | — | — | — | — | — | — | — | — | +2.5% | +2.6% | +5.2% | −0.8% |
EIS Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 20.61%
- 3-year Sharpe ratio: 1.73 (vs 4.5% risk-free rate)
- Best month: +16.69% (Nov 2023)
- Worst month: −14.43% (Oct 2023)
EIS Fund Flows
Monthly money in and out of iShares MSCI Israel ETF, from SEC Form N-PORT.
- 12-month net flow: $458.6M
- 12-month gross sales (incl. reinvestments): $503.6M
- Sales ÷ redemptions: 11.18×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $0 | $6.5M | −$6.5M |
| Apr 2026 | $0 | $25.3M | −$25.3M |
| Mar 2026 | $67.7M | $0 | $67.7M |
| Feb 2026 | $84.8M | $0 | $84.8M |
| Jan 2026 | $111.2M | $0 | $111.2M |
| Dec 2025 | $43.3M | $0 | $43.3M |
| Nov 2025 | $20.4M | $0 | $20.4M |
| Oct 2025 | $49.9M | $0 | $49.9M |
| Sep 2025 | $14.3M | $0 | $14.3M |
| Aug 2025 | $41.3M | $9.0M | $32.3M |
| Jul 2025 | $48.0M | $0 | $48.0M |
| Jun 2025 | $22.8M | $4.2M | $18.7M |
EIS Assets Under Management
Net assets of iShares MSCI Israel ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $1.03B |
| 2026-02-28 | $848.70M |
| 2025-11-30 | $528.42M |
| 2025-08-31 | $403.32M |
| 2025-05-31 | $271.80M |
| 2025-02-28 | $276.83M |
| 2024-11-30 | $177.21M |
| 2024-08-31 | $154.49M |
| 2024-05-31 | $154.86M |
| 2024-02-29 | $140.06M |
| 2023-11-30 | $130.39M |
| 2023-08-31 | $143.11M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.